Pleiotropic effects of taurine in treatment of a patient with diabetes mellitus
AbstractThe review presents data from experimental and clinical studies that indicate the possibility and ways of the effect of taurine on the level of glycemia, insulin resistance, dyslipidemia in patients with diabetes mellitus. Possible metabolic and molecular mechanisms of taurine in the treatment of cardiovascular pathology and microvascular complications in the considered category of patients are considered.
Keywords:diabetes mellitus; taurine
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Ametov A.S., Turkina S.V. Pleiotropic effects of taurine in treatment of a patient with diabetes mellitus. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2022; 11 (4): 78–88. DOI: https://doi.org/10.33029/2304-9529-2022-11-4-78-88 (in Russian)
References
1. Cho N.H., Shaw J.E., Karuranga S., et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018; 138: 271–81.
2. Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.А. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Saharniy diabet [Diabetes Mellitus]. 2021; 24 (3): 204–21. (in Russian)
3. Schaffer S., Kim H.W. Effects and mechanisms of taurine as a therapeutic agent. Biomol Ther (Seoul). 2018; 26 (3): 225–41.
4. Almeida C.C., Mendonça Pereira B.F., Leandro K.C., et al. Bioactive compounds in infant formula and their effects on infant nutrition and health: a systematic literature review. Int J Food Sci. 2021; 2021: 8850080.
5. Jagim A.R., Harty P.S., Barakat A.R., et al. Prevalence and amounts of common ingredients found in energy drinks and shots. Nutrients. 2022; 14 (2): 314.
6. De Luca A., Pierno S., Camerino D.C. Taurine: the appeal of a safe amino acid for skeletal muscle disorders. J Transl Med. 2015; 13: 243.
7. Yamori Y., Taguchi T., Hamada A., et al. Taurine in health and diseases: consistent evidence from experimental and epidemiological studies. J Biomed Sci. 2010; 17 (suppl 1): S 6.
8. Sak D., Erdenen F., Müderrisoglu C., et al. The relationship between plasma taurine levels and diabetic complications in patients with type 2 diabetes mellitus. Biomolecules. 2019; 9 (3): 96.
9. Agouza I.M.E., Saad A.H., Mahfouz A.A., Hamdy K. Serum taurine level in relation to ophthalmoscopic examination as early marker for diabetic retinopathy. Clin Med Biochem. 2017; 3 (1): 124.
10. Agouza I.M.E., Taha A., Mahfouz A.A., Shalash N.M., Taha K.H. The possibility of using serum taurine level as an early marker to control complications of diabetic foot. J Diabet Complications Med. 2017; 2: 116.
11. Wen C., Li F., Zhang L., et al. Taurine is involved in energy metabolism in muscles, adipose tissue, and the liver. Mol Nutr Food Res. 2019; 63 (2): e1800536.
12. Ginguay A., De Bandt J.P., Cynober L. Indications and contraindications for infusing specific amino acids. (leucine, glutamine, arginine, citrulline and taurine) in critical illness. Curr Opin Clin Nutr Metab Care. 2016; 19: 161–9.
13. Yamori Y., Murakami S., Ikeda K., Nara Y. Fish and life-style-related disease prevention: experimental and epidemiological evidence for anti-atherogenic potential of taurine. Clin Exp Pharmacol Physiol. 2004; 31: 20–3.
14. Sagara M., Murakami S., Mizushima S., et al. Taurine in 24-h urine samples is inversely related to cardiovascular risks of middle aged subjects in 50 populations of the world. Adv Exp Med Biol. 2015; 803: 623–36.
15. Rosa F.T., Freitas E.C., Deminice R., et al. Oxidative stress and inflammation in obesity after taurine supplementation: a double-blind placebo-controlled study. Eur J Nutr. 2014; 53: 823–30.
16. Schaffer S.W., Azuma J., Mozaffari M. Role of antioxidant activity of taurine in diabetes. Can J Physiol Pharmacol. 2009; 87: 91–9.
17. Ito T., Schaffer S.W., Azuma J. The potential usefulness of taurine on diabetes mellitus and its complications. Amino Acids. 2012; 42: 1529–39.
18. Imai M., Asano T., Murakami S. Potential role of taurine in prevention of diabetes and metabolic syndrome. Amino Acids. 2014; 46: 81–8.
19. Murakami S. Role of taurine in the pathogenesis of obesity. Mol Nutr Food Res. 2015; 59: 1353–63.
20. Chen W., Guo J., Zhang Y., Zhang J. The beneficial effects of taurine in preventing metabolic syndrome. Food Funct. 2016; 7: 1849–63.
21. Ametov A.S., Turkina S.V. Taurine is an amazing molecule in controlling metabolic syndrome. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (3): 44–51. (in Russian)
22. Tao X., Zhang Z., Yang Z., Rao B. The effects of taurine supplementation on diabetes mellitus in humans: a systematic review and meta-analysis. Food Chem (Oxf). 2022; 21 (4): e100106.
23. Miyazaki T., Ito T., Baseggio Conrado A., Murakami S. Editorial for special issue on “regulation and effect of taurine on metabolism”. Metabolites. 2022; 12: 795.
24. Zheng Y., Ceglarek U., Huang T., et al. Plasma taurine, diabetes genetic predisposition, and changes of insulin sensitivity in response to weight-loss diets. J Clin Endocrinol Metab. 2016; 101 (10): 3820–6. DOI: https://doi.org/10.1210/jc.2016-1760
25. Sarkar P., Basak P., Ghosh S., Kundu M., Sil P.C. Prophylactic role of taurine and its derivatives against diabetes mellitus and its related complications. Food Chem Toxicol. 2017; 110: 109–21.
26. Díaz-Rizzolo D.A., Serra A., Colungo C., et al. Type 2 diabetes preventive effects with a 12-months sardine-enriched diet in elderly population with prediabetes: an interventional, randomized and controlled trial. Clin Nutr. 2021; 40 (5): 2587–98.
27. Moludi J., Qaisar S.A., Kadhim M.M., et al. Protective and therapeutic effectiveness of taurine supplementation plus low calorie diet on metabolic parameters and endothelial markers in patients with diabetes mellitus: a randomized, clinical trial. Nutr Metab (Lond). 2022; 19: 49.
28. L’Amoreaux W.J., Cuttitta C., Santora A., et al. Taurine regulates insulin release from pancreatic beta cell lines. J Biomed Sci. 2010; 17 (suppl 1): 11.
29. Cuttitta C.M., Guariglia S.R., Idrissi A.E., L’amoreaux W.J. Taurine’s effects on the neuroendocrine functions of pancreatic β cells. Adv Exp Med Biol. 2013; 775: 299–310.
30. Ribeiro R.A., Bonfleur M.L., Batista T.M., et al. Regulation of glucose and lipid metabolism by the pancreatic and extra-pancreatic actions of taurine. Amino Acids. 2018; 50 (11): 1511–24.
31. Carneiro E.M., Latorraca M.Q., Araujo E., et al Taurine supplementation modulates glucose homeostasis and islet function. J Nutr Biochem. 2009; 20 (7): 503–11.
32. Maleki V., Alizadeh M., Esmaeili F., Mahdavi R. The effects of taurine supplementation on glycemic control and serum lipid profile in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Amino Acids. 2020; 52 (6–7): 905–14.
33. Kim K.S., Oh D.H., Kim J.Y., et al. Taurine ameliorates hyperglycemia and dyslipidemia by reducing insulin resistance and leptin level in Otsuka Long-Evans Tokushima fatty (OLETF) rats with long-term diabetes. Exp Mol Med. 2012; 44 (11): 665–73.
34. Ametov A.S., Kochergina I.I., Elizarova E.P. Experience with divicor used in type 2 diabetes. Рroblemy endokrinologii [Problems of Endocrinology]. 2007; 53 (4): 44–50. (in Russian)
35. Kudinov V.I., Zolotareva N.V., Shul’ga Yu.V. The study of the clinical efficacy of Dibicor in type II diabetes mellitus. Glavniy vrach. Farmatsiya [Chief Physician. Pharmacy]. 2007; 9 (1): 17–8. (in Russian)
36. Shestakova M.V., Chugunova L.A., Shamkhalova M. Sh. Experience with the use of Dibicor in type 2 diabetes mellitus. Saharniy diabet [Diabetes Mellitus] 2007; 10 (1): 30–1. (in Russian)
37. Mkrtumyan A.M., Podachina S.V., Petrachenko V.V. Dibicor is an effective and safe agent for the treatment of diabetes mellitus. Effektivnaya farmakoterapiya v endokrinologii [Effective Pharmacotherapy in Endocrinology]. 2008; (2): 34–9. (in Russian)
38. Severina T.I., Popkova E.N., Trel’skaya N. Yu., Emel’yanov V.V. Clinical and metabolic efficacy of Dibicor in patients with type 2 diabetes. Farmateka [Pharmateca]. 2011; (5): 126–9. (in Russian)
39. Yuzhakova A.E., Nelaeva A.A., Khasanova Yu.V. The role of taurine in the correction of carbohydrate metabolism disorders. Effektivnaya farmakoterapiya [Effective Pharmacotherapy]. 2019; 15 (22): 16–8. (in Russian)
40. Xu Y.J., Arneja A.S., Tappia P.S., Dhalla N.S. The potential health benefits of taurine in cardiovascular disease. Exp Clin Cardiol. 2008; 13 (2): 57–65.
41. Bkaily G., Jazzar A., Normand A., et al. Taurine and cardiac disease: state of the art and perspectives. Can J Physiol Pharmacol. 2020; 98 (2): 67–73.
42. Dong Y., Li X., Liu Y., Gao J., Tao J. The molecular targets of taurine confer anti-hyperlipidemic effects. Life Sci. 2021; 278: 119579. DOI: https://doi.org/10.1016/j.lfs.2021.119579
43. Tagawa R., Kobayashi M., Sakurai M., et al. Long-term dietary taurine lowers plasma levels of cholesterol and bile acids. Int J Mol Sci. 2022; 23: 179.
44. Nechaeva G.I., Druk I.V., Ryapolova E.A. Efficacy and tolerability of taurine in patients with type 2 diabetes mellitus and left ventricular diastolic dysfunction. Poliklinika [Polyclinic]. 2015; (1): 58–62. (in Russian)
45. Park T., Lee K. Dietary taurine supplementation reduces plasma and liver cholesterol and triglyceride levels in rats fed a high-cholesterol or a cholesterol-free diet. Adv Exp Med Biol. 1998; 442: 319–25.
46. Choi M.J., Kim J.H., Chang K.J. The effect of dietary taurine supplementation on plasma and liver lipid concentrations and free amino acid concentrations in rats fed a high-cholesterol diet. Adv Exp Med Biol. 2006; 583: 235–42.
47. Lewis M., Littlejohns B., Lin H., Angelini G.D., Suleiman M.S. Cardiac taurine and principal amino acids in right and left ventricles of patients with either aortic valve stenosis or coronary artery disease: the importance of diabetes and gender. Springerplus. 2014; 13 (3): 523.
48. Inam-U-Llah, Piao F., Aadil R.M., Suleman R., et al. Ameliorative effects of taurine against diabetes: a review. Amino Acids 2018; 50 (5): 487–502.
49. Manna P., Das J., Sil P.C. Role of sulfur containing amino acids as an adjuvant therapy in the prevention of diabetes and its associated complications. Curr Diabetes Rev. 2013; 9 (3): 237–48.
50. Tappia P.S., Thliveris J., Xu Y.J., et al. Effects of amino acid supplementation on myocardial cell damage and cardiac function in diabetes. Exp Clin Cardiol. 2013; 16 (3): 17–22.
51. Тappia P.S., Xu Y.J., Rodriguez-Leyva D., Aroutiounova N., Dhalla N.S. Cardioprotective effects of cysteine alone or in combination with taurine in diabetes. Physiol Res. 2013; 62 (2): 171–8.
52. Тappia P.S., Adameova A., Dhalla N.S. Attenuation of diabetes-induced cardiac and subcellular defects by sulphur-containing amino acids. Curr Med Chem. 2018; 25 (3): 336–45.
53. Statsenko M.E., Shilina N.N., Vinnikova A.A. Possibilities of taurine in the complex therapy of patients with chronic heart failure and type 2 diabetes. Meditsinskiy alfavit [Medical Alphabet]. 2015; 4 (1): 5–10. (in Russian)
54. Statsenko M.E., Turkina S.V., Shilina N.N. Liver damage in patients with chronic ischemic heart failure and type 2 diabetes mellitus – an insidious tandem: the possibility of additional organoprotective therapy. Consilium Medicum. 2016; 18 (5): 103–9. (in Russian)
55. Schaffer S.W., Shimada-Takaura K., Jong C.J., et al. Impaired energy metabolism of the taurine-deficient heart. Amino Acids. 2016; 48: 549–58.
56. Azuma M., Takahashi K., Fukuda T., et al. Taurine attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac myocytes. Eur J Pharmacol. 2000; 403 (3): 181–8.
57. Mahmoud A.M. Exercise amaliorates metabolic disturbances and oxidative stress in diabetic cardiomyopathy: possible underlying mechanisms. Adv Exp Med Biol. 2017; 999: 207–30.
58. Abebe W., Mozaffari M.S. Role of taurine in the vasculature: an overview of experimental and human studie. Am J Cardiovasc Dis. 2011; 1 (3): 293–311.
59. Fennessy F., Moneley D.S., Wang J.H., et al. Taurine and vitamin C modify monocyte and endothelial dysfunction in young smokers. Circulation. 2003; 107 (3): 410–5.
60. Li M., Wu Y., Ye L. The role of amino acids in endothelial biology and function. Cells. 2022; 11: 372.
61. Frantz S., Ertl G., Bauersachs J. Mechanisms of disease: toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2007; 4: 444–54.
62. Lu Z., Zhang X., Li Y., Lopes-Virella M.F., Huang Y. TLR 4 antagonist attenuates atherogenesis in LDL receptor-deficient mice with diet-induced type 2 diabetes. Immunobiology. 2015; 220: 1246–54.
63. Dasu M.R., Devaraj S., Park S., Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care. 2010; 33: 861–8.
64. Qaradakhi T., Gadanec L.K., et al. the anti-inflammatory effect of taurine on cardiovascular disease. Nutrients. 2020; 12: 2847.
65. Rezvan V.V., Vasil’eva I.S., Dvoretsky L.I. Efficacy of taurine in the treatment of stress angina in patients with postinfarction cardiosclerosis. Klinicheskaya meditsina [Clinical Medicine]. 2020; 98 (1): 20–7. (in Russian)
66. Statsenko M.E., Turkina S.V., Shilina N.N., Vinnikova A.A. Endothelium protecting properties of taurin in chronic heart failure with type 2 diabetes. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2016; 15 (2): 38–44. (in Russian)
67. Statsenko M.E., Vinnikova A.A., Shilina N.N., Ronskaya A.M. Possibilities of Dibicor in the correction of metabolic and vascular disorders in patients with chronic heart failure and type 2 diabetes mellitus. Farmateka [Pharmateca]. 2014; (4): 33–40. (in Russian)
68. Gordeev I.G., Pokrovskaya E.M., Luchinkina E.E. Taurine effects on the occurrence of cardiac arrhythmias and QT interval dispersion in patients with postinfarction cardiosclerosis and chronic heart failure: a comparative randomised study. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2012; 11 (1): 63–8. (in Russian)
69. Svarovskaya A.V., Garganeeva A.A. Evaluation of the effect of taurine on the course of coronary artery disease associated with diabetes of the 2nd type, in patients undergoing coronary revascularization. Meditsinskiy sovet [Medical Council]. 2018; (16): 94–9. (in Russian)
70. Fan Y., Lai J., Yuan Y., et al. Taurine protects retinal cells and improves synaptic connections in early diabetic rats. Curr Eye Res. 2020; 45 (1): 52–63.
71. Castelli V., Paladini A., d’Angelo M., et al. Taurine and oxidative stress in retinal health and disease. CNS Neurosci Ther. 2021; 27 (4): 403–12.
72. Statsenko M.E., Turkina S.V., Shilina N.N., Vinnikova A.A. The place of taurine in the complex treatment of patients with chronic heart failure and type 2 diabetes mellitus. RMZh [RMJ]. 2015; (8): 472–76. (in Russian)
73. Chesney R.W., Patters A.B., Han X. Taurine and the kidneys. In: A. El Idrissi, W. L’Amoreaux (eds). Taurine in Health and Disease. Kerala, India: Transworld Research Network, 2011.
74. Higo S., Miyata S., Jiang Q.Y., et al. Taurine administration after appearance of proteinuria retards progression of diabetic nephropathy in rats. Kobe J Med Sci. 2008; 54 (1): 35–45.
75. Winiarska K., Szymanski K., Gorniak P., Dudziak M., Bryla J. Hypoglycaemic, antioxidative and nephroprotective effects of taurine in alloxan diabetic rabbits. Biochimie. 2009; 91: 261–70.
76. Lee E.A., Seo J.Y., Jiang Z., et al. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. Kidney Int. 2005; 67: 1762–71.
77. Huang J.S., Chuang L.Y., Guh J.Y., Huang Y.J., Hsu M.S. Antioxidants attenuate high glucose-induced hypertrophic growth in renal tubular epithelial cells. Am J Physiol Renal Physiol. 2007; 293: F1072–82.
78. Miyata M., Funaki A., Fukuhara C., et al. Taurine attenuates hepatic steatosis in a genetic model of fatty liver disease. J Toxicol Sci. 2020; 45 (2): 87–94.
79. Qi Song, Junxia Guo, Yanzhen Zhang, Wen Chen. The beneficial effects of taurine in alleviating fatty liver disease. J Funct Foods. 2021; 77: 104351.
80. Statsenko M.E., Turkina S.V., Shilina N.N., Gorbacheva E.E., Ermolenko A.A. Pharmacotherapy of non-alcoholic fatty liver disease: focus on fibrosis. RMZh. Meditsinskoe obozrenie [RMJ. Medical Review]. 2018; 2 (7): 59–63. (in Russian)
81. Lazebnik L.B., Golovanova E.V., Turkina S.V., et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Eksperimental’naya i klinicheskaya gastroenterologiya [Experimental and Clinical Gastroenterology]. 2021; 185 (1): 4–52. (in Russian)